<DOC>
	<DOCNO>NCT00808184</DOCNO>
	<brief_summary>The objective study : To correlate pharmacokinetic parameter raltegravir midazolam irinotecan ( CPT-11 ) metabolite SN-38 . To correlate genotype UGT1A1 patient receive CPT-11 chemotherapy irinotecan raltegravir pharmacokinetic parameter . To model pharmacokinetic pharmacodynamic behaviour CPT-11 study population .</brief_summary>
	<brief_title>Pharmacokinetic Study CPT-11 , Raltegravir Midazolam With Characterisation UGT1A1 Genotype</brief_title>
	<detailed_description>To correlate pharmacokinetic parameter raltegravir midazolam irinotecan ( CPT-11 ) metabolite SN-38 . To correlate genotype UGT1A1 patient receive CPT-11 chemotherapy irinotecan raltegravir pharmacokinetic parameter . To model pharmacokinetic pharmacodynamic behaviour CPT-11 study population . VI . Abstract Research Proposal In 300 word , describe concisely specific aim , hypothesis , methodology approach application , indicate appropriate application 's importance science medicine . The abstract must self-contained serve succinct accurate description application separate . Please use lay term . If possible , technical medical term explain simple language . The pharmacokinetic parameter raltegravir correlate well irinotecan ( CPT-11 ) metabolite SN-38 good midazolam . Raltegravir pharmacokinetic parameter use predict genotype UGT1A1 patient receive CPT-11 chemotherapy irinotecan . Patients prescribe CPT-11 contain regimen FOLFIRI select study . Subjects undergo raltegravir midazolam test one day first dose chemotherapy . Pharmacokinetic sample occur 2 day . The raltegravir midazolam test carry fasting condition ( minimum 10 hour ) . Between 8 9 , one mg midazolam administer intravenously 30 second . At time , raltegravir 400 mg administer orally water . Blood sample draw specify time pharmacokinetic analysis heparinised butterfly needle opposite arm . On next day , FOLFIRI administer follow : CPT-11 180 mg/m2 250 mL Normal Saline 90 min follow Leucovorin 400 mg/m2 250 mL Normal Saline 2 hour follow 5-Flourouracil 400 mg/m2 IV bolus follow 5-Flourouracil 2400 mg/m2 46 hour . Premedications may administer per routine clinical practice . Blood take specify time pharmacokinetic analysis . The pharmacokinetic parameter raltegravir midazolam compare pharmacokinetic parameter CPT-11 metabolite SN-38 . Correlation analysis perform parameter find raltegravir midazolam parameter correlate best CPT-11 SN-38 parameter . CPT-11 raltegravir parameter correlate UGT1A1 demographic information .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Histologically cytologically proven solid tumour CPT11 give Folfiri regimen indicate prescribed attend physician . Age 21 year . Measurable evaluable disease Karnofsky performance status &gt; 70 % Life expectancy &gt; 3 month WBC &gt; 3.0 x 103/ ? l ; ANC &gt; 1500/ ? l Hemoglobin &gt; 9.0 g/dl Platelets &gt; 100000/ ? l Creatinine &lt; 1.5 x ULN calculate creatinine clearance &gt; 40 ml/min Total bilirubin &lt; 1.5 x ULN SGOT , SGPT &lt; 5 x ULN unless due disease Biologic therapy chemotherapy within 4 week . ( Six week prior nitrosoureas mitomycin C ) . Radiation therapy within 4 week &gt; 25 % bone marrow irradiate . Have receive medication know metabolised UGT1A1 within 30 day first dose CPT11 . Short gut syndrome cause malabsorption . Colony stimulate factor within 2 week . Women childbearing potential practice birth control . ( Note : mean oral contraception ) Pregnant woman Severe peripheral neuropathy grade 2 high . Medical psychiatric condition may impair patient 's ability provide inform consent . Hypersensitivity CPT11 , raltegravir midazolam/other benzodiazepine . Rapidly progressive intracranial spinal metastatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Histologically cytologically proven solid tumour CPT-11 give Folfiri regimen</keyword>
</DOC>